Follow
Dr Jyoti Nangalia
Dr Jyoti Nangalia
Wellcome Sanger Institute
Verified email at sanger.ac.uk
Title
Cited by
Cited by
Year
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J Nangalia, CE Massie, EJ Baxter, FL Nice, G Gundem, DC Wedge, ...
New England Journal of Medicine 369 (25), 2391-2405, 2013
21102013
Pan-cancer analysis of whole genomes
Nature 578 (7793), 82-93, 2020
1641*2020
Effect of mutation order on myeloproliferative neoplasms
CA Ortmann, DG Kent, J Nangalia, Y Silber, DC Wedge, J Grinfeld, ...
New England Journal of Medicine 372 (7), 601-612, 2015
5862015
Classification and personalized prognosis in myeloproliferative neoplasms
J Grinfeld, J Nangalia, EJ Baxter, DC Wedge, N Angelopoulos, R Cantrill, ...
New England Journal of Medicine 379 (15), 1416-1430, 2018
5472018
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer
YS Ju, LB Alexandrov, M Gerstung, I Martincorena, S Nik-Zainal, ...
elife 3, e02935, 2014
3882014
The mutational landscape of normal human endometrial epithelium
L Moore, D Leongamornlert, THH Coorens, MA Sanders, P Ellis, ...
Nature 580 (7805), 640-646, 2020
3812020
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
RA Mesa, AM Vannucchi, A Mead, M Egyed, A Szoke, A Suvorov, ...
The Lancet Haematology 4 (5), e225-e236, 2017
2772017
Extensive heterogeneity in somatic mutation and selection in the human bladder
ARJ Lawson, F Abascal, THH Coorens, Y Hooks, L O’Neill, C Latimer, ...
Science 370 (6512), 75-82, 2020
2122020
Myeloproliferative neoplasms: from origins to outcomes
J Nangalia, AR Green
Hematology 2014, the American Society of Hematology Education Program Book …, 2017
1872017
Clonal dynamics of haematopoiesis across the human lifespan
E Mitchell, M Spencer Chapman, N Williams, KJ Dawson, N Mende, ...
Nature 606 (7913), 343-350, 2022
1842022
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
W Tapper, AV Jones, R Kralovics, AS Harutyunyan, K Zoi, W Leung, ...
Nature communications 6 (1), 6691, 2015
1832015
The longitudinal dynamics and natural history of clonal haematopoiesis
MA Fabre, JG de Almeida, E Fiorillo, E Mitchell, A Damaskou, J Rak, ...
Nature 606 (7913), 335-342, 2022
1722022
Life histories of myeloproliferative neoplasms inferred from phylogenies
N Williams, J Lee, E Mitchell, L Moore, EJ Baxter, J Hewinson, KJ Dawson, ...
Nature 602 (7895), 162-168, 2022
1592022
Inactivating CUX1 mutations promote tumorigenesis
CC Wong, I Martincorena, AG Rust, M Rashid, C Alifrangis, ...
Nature genetics 46 (1), 33-38, 2014
1592014
A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline
M McMullin, C Harrison, S Ali, C Cargo, F Chen, J Ewing, M Garg, ...
British journal of haematology 184 (2), 2018
1472018
DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
J Nangalia, FL Nice, DC Wedge, AL Godfrey, J Grinfeld, C Thakker, ...
Haematologica 100 (11), e438, 2015
1252015
The evolving genomic landscape of myeloproliferative neoplasms
J Nangalia, TR Green
Hematology 2014, the American Society of Hematology Education Program Book …, 2014
1152014
Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms
J Grinfeld, J Nangalia, AR Green
Haematologica 102 (1), 7, 2017
1102017
Lineage tracing of human development through somatic mutations
M Spencer Chapman, AM Ranzoni, B Myers, N Williams, THH Coorens, ...
Nature 595 (7865), 85-90, 2021
972021
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline
MFF McMullin, AJ Mead, S Ali, C Cargo, F Chen, J Ewing, M Garg, ...
British journal of haematology 184 (2), 161, 2019
902019
The system can't perform the operation now. Try again later.
Articles 1–20